Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Private equity in 2025: Oakley, Triton, and Generali weigh liquidity strains, AI promises, and defence investing
Private equity in 2025: Oakley, Triton, and Generali weigh liquidity strains, AI promises, and defence investing European private equity entered 2025 with a striking split between portfolio resilience and industry-wide constraints. Speaking at the Largest DACH-focused...
Big Ten eyes $2bn private capital deal to launch new commercial arm
Big Ten eyes $2bn private capital deal to launch new commercial arm The Big Ten Conference is in advanced discussions over a private capital transaction worth at least $2bn that would establish a new commercial vehicle, Big Ten Enterprises, to consolidate its media...
BC Partners and Pollen Street ready £2bn Shawbrook IPO in London
BC Partners and Pollen Street ready £2bn Shawbrook IPO in London Shawbrook, the UK challenger bank owned by BC Partners and Pollen Street, is preparing to file for an initial public offering in London that could value the business at as much as £2bn ($2.7bn),...